|
GENTAUR
Tel: +32 16 58 90 45
Fax: + 32 16 50 90 45
info@genprice.com
Av. de l'Armée 68
• B-1040 BRUSSELS • BELGIUM
GENTAUR FRANCE
Tel: 01 43 25 01 50
9, Rue Lagrange
• 75005 PARIS • FRANCE
| |
D-1000 Docetaxel, >99%
[Taxotere] [RP 56976]
| M.W. 807.89 |
C43H53NO14
|
[114977-28-5] |
M.I. 13: 3431 |
Storage: Store at or below -20 ºC. Solubility:
Soluble in DMSO. Disposal: A
 | Docetaxel, a semisynthetic analog of paclitaxel, shares the latter's
mechanism of action: the promotion of microtubule assembly and inhibition of
microtubule disassembly. This anti-mitotic behavior results in apoptosis of
human leukemia HL-60 cells arrested at the M phase in the cell cycle.
Pazdur, R., et al. "The taxoids: paclitaxel (Taxol) and docetaxel
(Taxotere)." Cancer Treat Rev. 19: 351-386 (1993).
Hagisawa, S., et al. "Docetaxel-induced apoptosis in the mitotic
phase: electron microscopic and cytochemical studies of human leukemia
cells." Med Electron Microsc. 32: 167-174 (1999). |
| Docetaxel has exhibited significant antitumor activity against prostate
cancer, metastatic breast cancer, gatric cancer, and others. Pienta, K.J.
"Preclinical mechanisms of action of docetaxel and docetaxel combinations in
prostate cancer." Semin Oncol. 4: 3-7 (2001). Yoshida, K.,
et al. "Phase I study of combination therapy with S-1 and docetaxel
(TXT) for advanced or recurrent gastric cancer." Anticancer Res.
24: 1843-1851 (2004). Tabernero, J., et al. "A multicentre,
randomised phase II study of weekly or 3-weekly docetaxel in patients with
metastatic breast cancer." Ann Oncol. 15: 1358-1365 (2004). |
|
